China has exhibited one of the most transformational evolutions ever seen in emerging markets (EMs), with its weight in the MSCI EM Index doubling over the past five years. But China’s own dynamic and mega-cap stocks have somehow skewed EM benchmarks’ performance. We believe that beyond China, EMs offer an attractive and differentiated opportunity set—one which drove our launch of our EM ex China Growth strategy. In this Q&A, Romina Graiver, partner, a portfolio specialist on our global equity team, discusses the opportunity set and process driving our strategy.
Investment Management
Emerging Markets—Beyond China
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
More News and Insights
Inari Medical, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Inari Medical, Inc. (NARI $54.73), a medical device company that develops interventional products for patients suffering from venous diseases.
Read moreGifting Appreciated Securities to a Donor-Advised Fund Program
This charitable vehicle provides a simplified approach that allows you to maximize your charitable donations and tax benefits—an approach that can transform the way you give.
Read moreClio Valued at $3B in $900M Series F Investment Led by NEA
William Blair acted as the exclusive financial advisor to Clio in connection with its $900 million Series F investment round led by New Enterprise Associates, at a $3.0 billion valuation.
Read more